Could 3 x 20mg of Oxycontin own make happen demise?
Answers: Following is the Letter sent to Health Care Professionals in 2001 when second warnings be added to Oxycotin.
July 18, 2001
Dear Health Care Professional,
Reports of illegal misuse, ill-treat, and diversion of OxyContin`O Tablets from various parts of the country own prompted Purdue Pharma L.P. to revise sections of the prescribing information, specifically 1) WARNINGS (including a spanking new Box Warning) which call attention to the potential for misuse, invective and diversion and 2) INDICATIONS which reinforces the appropriate patient population for whom this product is intended.
OxyContin`O is an opioid agonist and a Schedule II controlled substance near an abuse liability similar to morphine. This should be considered when prescribing or dispensing OxyContin`O surrounded by situations where the prescriber or pharmacist is concerned more or less an increased risk of misuse, abuse, or diversion. While concerns nearly abuse, addiction, and diversion should not prevent the proper nouns of pain, healthcare professionals should be alert to the problems of misuse, knock about, and diversion.
The labeling changes will be implement within the subsequent several weeks. In the meantime, we want you to be aware of this important sanctuary information. Listed below are highlights of important change to WARNINGS and INDICATIONS. You should consult the full prescribing information accompanying this letter for adjectives of the changes.
The following BOX WARNING have been added:
WARNING:
OxyContin`O is an opioid agonist and a Schedule II controlled substance beside an abuse liability similar to morphine.
Oxycodone can be abused within a manner similar to other opioid agonists, court or illicit. This should be considered when prescribing or dispensing OxyContin`O in situations where on earth the physician or pharmacist is concerned about an increased risk of misuse, misuse, or diversion.
OxyContin(R) Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe backache when a continuous, around-the-clock analgesic is needed for an extended period of time.
OxyContin(R) tablets are NOT intended for use as a prn analgesic.
OxyContin(R) 80 mg and 160 mg Tablets ARE FOR USE IN OPIOID TOLERANT PATIENTS ONLY. These tablet strengths may grounds fatal respiratory depression when administered to patients not previously exposed to opioids.
OxyContin`O (oxycodone hydrochloride controlled-release) TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, OR CRUSHED. TAKING BROKEN, CHEWED OR CRUSHED OxyContin`O TABLETS LEADS TO A RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF OXYCODONE.
This is also reinforced surrounded by WARNINGS.
The INDICATIONS AND USAGE section immediately reads:
OxyContin`O tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the supervision of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended term of time.
OxyContin(R) is NOT intended for use as a prn analgesic.
Physicians should individualize treatment in every luggage, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as nonsteroidal anti-inflammatory drugs and acetaminophen, to opioids within a plan of pain regulation such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality [formerly known as the Agency for Health Care Policy and Research], the Federation of State Medical Boards Model Guidelines, or the American Pain Society.
OxyContin`O is not indicated for spasm in the on the spot post-operative period (the first 12-24 hours following surgery), or if the twinge is mild, or not expected to persist for an extended spell of time. OxyContin`O is only indicated for post-operative use if the long-suffering is already receiving the drug prior to surgery or if the postoperative headache is expected to be moderate to severe and persist for an extended extent of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)
It is important that you forward any adverse event information associated near the use of OxyContin`O Tablets to Purdue Pharma L.P. at 1-8BB-726-7535 (prompt #2). You can also report this information directly to the FDA via the MedWatch system at 1-8OO-FDA-1088, by fax at 1-8OO-FDA-0178, by mail (using a postage-paid form), or the internet at www.fda.gov/medwatch.
If you own any questions on how to prevent and detect treat roughly or diversion of this product, you should contact your State Professional Licensing Board or State Controlled Substances Authority for information.
The abuse and diversion of prescription drugs have become a significant public health issue contained by the United States. Purdue Pharma L.P. is proud to be the first pharmaceutical manufacturer to voluntarily revise prescribing information for a Schedule II opioid contained by order to address the issue of verbal abuse and diversion.
Sincerely,
Robert F. Reder, MD
Vice President, Medical Affairs and Worldwide Drug Safety
my nanny takes alot of that stuff but i dont no how much...but shes dieing of cancer
More Questions and Answers ...